Skip to main content
HairCited

피나스테리드 관련 안드로겐성 탈모

A

총 18,623명의 참여자를 대상으로 한 129건의 연구(메타분석 16건, RCT 13건)에 근거합니다. 129건 중 106건의 연구에서 긍정적인 효과가 나타났습니다.

<\/script>\n
`; }, get iframeSnippet() { const domain = 'haircited.com'; const params = 'ingredient\u003Dfinasteride\u0026condition\u003Dandrogenetic\u002Dalopecia'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style



      
      
    

Widget powered by . Free, no account required.

A

결론

Finasteride has very strong evidence supporting its effectiveness for androgenetic alopecia and is considered a well-established first-line option backed by decades of research.

  • 106 out of 129 studies show positive effects — one of the most studied hair loss interventions
  • 16 meta-analyses and 13 RCTs provide a robust evidence base across 18,623 participants
  • Works by reducing DHT, the hormone primarily responsible for pattern hair loss
  • Topical finasteride formulations are being researched as an alternative to oral use

Key Study Findings

Review
Androgenetic Alopecia in Women: A Narrative Review of Pathophysiology, Clinical Evaluation, and Treatments.
Dose: None vs: None Outcome: None 효과: None None

대상 집단: women with androgenetic alopecia (female pattern hair loss)

non-randomized controlled trial n=60 16 weeks Open-label
Clinical Efficacy and Mechanisms of Microneedling Alone or Combined With Drugs in the Treatment of …
Dose: Mild group: microneedling alone (8 weeks); Moderate group: microneedling + 5% minoxidil (12 weeks); vs: Placebo 효과: All groups showed significant decrease in HLSS and increase in hair density post-treatment (p<0.001) p<0.001
randomized controlled trial n=45 16 weeks Open-label
Clinical and Trichoscopic Evaluations of Topical Finasteride 1%, Topical Spironolactone 5%, and Minoxidil 5% in …
Dose: Group A: topical finasteride 1% solution; Group B: topical spironolactone 5% solution; Group C: topi vs: Placebo 효과: Groups A and C showed significant improvement on Sinclair scale and trichoscopic hair density; Group None
Review
Male and female pattern hair loss.
Dose: None vs: Placebo 효과: None None
randomized controlled trial n=45 Open-label
Clinical efficacy of microneedle combined with 5% Minoxidil solution and finasteride in the treatment of …
Dose: Group A: 5% Minoxidil alone; Group B: 5% Minoxidil + Finasteride; Group C: Microneedling + 5% Minoxi vs: Placebo 효과: Hair density and hair shaft diameter increased in all groups; Group C superior to Group A in Norwood p<0.01

Key Statistics

206

연구

24777

참여자

Positive

A

등급

Referenced Papers

Aesthetic plastic surgery 2025 14 인용
Anais brasileiros de … 2025 7 인용
International journal of … 2025 5 인용
Journal of cosmetic … 2025 3 인용
European journal of … 2025 3 인용
Australian prescriber 2025 2 인용
Skin appendage disorders 2025 1 인용
Nature reviews. Disease … 2025
Annals of dermatology 2025
International journal of … 2024 39 인용
Indian journal of … 2024 14 인용
Dermatology (Basel, Switzerland) 2024 14 인용
Journal of cosmetic … 2024 11 인용
Journal of clinical … 2024 10 인용
Facial plastic surgery … 2024 8 인용
American family physician 2024 8 인용
Photodermatology, photoimmunology & … 2024 8 인용
International journal of … 2024 5 인용
Drugs 2023 221 인용
JAAD international 2023 80 인용
Clinical, cosmetic and … 2023 58 인용
American journal of … 2023 41 인용
Anais brasileiros de … 2023 29 인용
Journal der Deutschen … 2023 5 인용
Journal of cosmetic … 2023 3 인용
BMJ case reports 2023 2 인용
Clinics in plastic … 2023 1 인용
International journal of … 2023 1 인용
The Journal of … 2022 65 인용
Faculty reviews 2022 44 인용
Dermatologic therapy 2022 41 인용
Archivos espanoles de … 2022 9 인용
Cureus 2022 3 인용
Facial plastic surgery … 2022
Journal of cutaneous … 2021 44 인용
Journal of the … 2021 42 인용
Expert opinion on … 2020 147 인용
Fertility and sterility 2020 94 인용
Neurobiology of stress 2020 72 인용
Facial plastic surgery … 2020 15 인용
Dermatologic clinics 2020 15 인용
Alternative therapies in … 2020 11 인용
Journal of cosmetic … 2019 100 인용
Assay and drug … 2019 19 인용
The aging male … 2019 19 인용
Indian journal of … 2018 79 인용
Expert opinion on … 2018 38 인용
Endocrine 2017 442 인용
JAMA dermatology 2017 121 인용
Current clinical pharmacology 2017 62 인용
Actas dermo-sifiliograficas 2017 17 인용
Deutsches Arzteblatt international 2016 99 인용
The Cochrane database … 2016 18 인용
Indian journal of … 2016 8 인용
Current problems in … 2015 8 인용
Der Internist 2015
Expert opinion on … 2014 57 인용
Current opinion in … 2014 43 인용
Giornale italiano di … 2014 8 인용
Indian journal of … 2013 196 인용
Dermatologic clinics 2013 78 인용
Journal of cosmetic … 2013 62 인용
Facial plastic surgery … 2013 16 인용
International journal of … 2013
Expert opinion on … 2010 264 인용
Current opinion in … 2009 54 인용
Seminars in cutaneous … 2009 4 인용
American family physician 2009
Nihon rinsho. Japanese … 2008 6 인용
Endocrinology and metabolism … 2007 33 인용
Acta dermatovenerologica Alpina, … 2005
Revue medicale de … 2004
Praxis 2003 28 인용
American family physician 2003
Molecular and cellular … 2002
American journal of … 2000 18 인용
Southern medical journal 2000
International journal of … 1999
American family physician 1999
Journal of the … 1999
Current pharmaceutical design 1999
Journal of cutaneous … 1999
Dermatologic clinics 1998 121 인용
Annales de dermatologie … 1997

Dosage & Usage

mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units

일반적으로 사용되는 용량

hairloss:
1 mg/day oral

상한량: 5 mg/day (BPH dose)

연구에서 사용된 용량

용량 기간 효과 N
None -- Neutral --
None -- Neutral --
Mild group: microneedling alone (8 weeks); Moderate group: microneedling + 5% minoxidil (12 weeks); 16 weeks Positive 60
Group A: topical finasteride 1% solution; Group B: topical spironolactone 5% solution; Group C: topi 16 weeks Positive 45
None -- Positive --
Group A: 5% Minoxidil alone; Group B: 5% Minoxidil + Finasteride; Group C: Microneedling + 5% Minoxi -- Positive 45
None -- Positive --
various across included studies (2015-2024) -- Positive --

권장 복용 시간: Once daily at the same time, with or without food

Safety & Side Effects

보고된 부작용

  • Decreased libido (2-4% of users)
  • Erectile dysfunction (1-3% of users)
  • Decreased ejaculate volume
  • Breast tenderness or gynecomastia (rare)
  • Depression or mood changes (rare, debated)

알려진 상호작용

  • No significant drug-drug interactions identified
  • May affect PSA test results (reduces PSA by ~50%)
  • Contraindicated in pregnancy (Category X teratogen)

일일 최대 섭취 허용량: 5 mg/day (BPH dose)

건강기능식품을 복용하기 전에 반드시 의료 전문가와 상담하십시오.

Frequently Asked Questions

Does 피나스테리드 help with 안드로겐성 탈모?
Based on 206 studies with 24,777 participants, there is strong evidence from multiple clinical trials that 피나스테리드 may support 안드로겐성 탈모 management. Our evidence grade is A (Strong Evidence).
How much 피나스테리드 should I take for 안드로겐성 탈모?
Studies have used various dosages. A commonly studied range is 1 mg/day oral. Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of 피나스테리드?
Reported side effects may include Decreased libido (2-4% of users), Erectile dysfunction (1-3% of users), Decreased ejaculate volume, Breast tenderness or gynecomastia (rare). Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for 피나스테리드 and 안드로겐성 탈모?
We rate the evidence as Grade A (Strong Evidence). This rating is based on 206 peer-reviewed studies with 24,777 total participants. The overall direction of effect is positive.

Related Evidence

FDA 면책 조항: 이 내용은 미국 식품의약국(FDA)의 평가를 받지 않았습니다. 이 웹사이트의 제품 및 정보는 질병의 진단, 치료, 완치 또는 예방을 목적으로 하지 않습니다. 제시된 근거 등급은 발표된 동료 심사 연구에 대한 우리의 분석에 기반하며, 의학적 조언을 구성하지 않습니다. 건강기능식품 복용을 시작하기 전에 반드시 의료 전문가와 상담하십시오.